Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.31 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21688122 | 0.95 | ALDH1A1 (0.38) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687515 | 0.92 | ALDH1A1 (0.35) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687892 | 0.91 | ALDH1A1 (0.38) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687676 | 0.91 | ALDH1A1 (0.37) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687532 | 0.88 | PTGER4 (0.31) | PTGER4STSKDM4EATML3MBTL1 | |
| SCHEMBL21687534 | 0.88 | PTGER4 (0.32) | ALDH1A1PTGER4KDM4EATML3MBTL1 | |
| SCHEMBL21687669 | 0.88 | ALDH1A1 (0.40) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21688072 | 0.88 | ALDH1A1 (0.35) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687664 | 0.87 | ALDH1A1 (0.39) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21688180 | 0.86 | ALDH1A1 (0.38) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-12-14 | — | — | US | disclosed |
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | CRY1, CCNL2, CCNE2 | ALDH1A1 616/4885LMNA 1582/4885HPGD 2175/4885 |
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | CRY1, CCNL2, CCNE2 | ALDH1A1 616/4885LMNA 1582/4885HPGD 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.